Study · Randomized controlled trial · n = 35 · 2022

5 results

Teriparatide and pelvic fracture healing: a phase 2 randomized controlled trial.

Nieves JW, Cosman F, McMahon D, Redko M, Hentschel I, Bartolotta R, Loftus M, Kazam JJ, Rotman J, Lane J

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA12 Aug 2021Cited by 18 (Europe PMC)

PMID34383100PMCIDPMC8758515DOI10.1007/s00198-021-06065-4PepBankPUB-34383100

Source link PubMedAsk about this study

Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

01HumanRandomized controlled trialEfficacy outcome
In pelvic-fracture patients, teriparatide did not improve cortical bridging scores versus placebo at three months, including after covariate adjustment.
In plain wordsIn pelvic-fracture patients, teriparatide did not improve bone-bridging scores versus placebo at three months.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeCortical bridging score
Study
n = 35
Comparator
Placebo
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 μg/day · subcutaneous · 3 monthsAs given in this study (human).
Source sentences
Summary
The intention to treat analysis showed no group difference in cortical bridging score, and 50% of fractures in TPTD-treated and 53% of fractures in placebo-treated patients were healed at 3 months, unchanged after adjustment for age, sacral fracture, and fracture displacement.
2 context sentences(design, population, supporting numbers)
Summary · context
Pelvic fracture patients were randomized to blinded daily subcutaneous teriparatide (TPTD) or placebo to assess healing and functional outcomes over 3 months.
Summary · context
This randomized, placebo-controlled study enrolled 35 patients (women and men >50 years old) within 4 weeks of pelvic fracture and evaluated the effect of blinded TPTD vs placebo over 3 months on fracture healing.
Report a problemFND-3438310001
02HumanRandomized controlled trialEfficacy outcome
In pelvic-fracture patients, healed fractures at three months were similar with teriparatide and placebo.
In plain wordsIn pelvic-fracture patients, healing at three months was similar with teriparatide and placebo.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeHealed fractures at three months
Study
n = 35
Comparator
Placebo
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 μg/day · subcutaneous · 3 monthsAs given in this study (human).
Measurements
Healed fractures
50%
Teriparatide
Healed fractures
53%
Placebo
Source sentences
Summary
The intention to treat analysis showed no group difference in cortical bridging score, and 50% of fractures in TPTD-treated and 53% of fractures in placebo-treated patients were healed at 3 months, unchanged after adjustment for age, sacral fracture, and fracture displacement.
2 context sentences(design, population, supporting numbers)
Summary · context
Pelvic fracture patients were randomized to blinded daily subcutaneous teriparatide (TPTD) or placebo to assess healing and functional outcomes over 3 months.
Summary · context
This randomized, placebo-controlled study enrolled 35 patients (women and men >50 years old) within 4 weeks of pelvic fracture and evaluated the effect of blinded TPTD vs placebo over 3 months on fracture healing.
Report a problemFND-3438310002
03HumanRandomized controlled trialEfficacy outcome
In pelvic-fracture patients, median pain scores fell in both the teriparatide and placebo groups, and teriparatide did not reduce pain more than placebo.
In plain wordsIn pelvic-fracture patients, pain fell in both groups, and teriparatide did not reduce pain more than placebo.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changePain score
Study
n = 35
Comparator
Placebo
Outcome group
Pain · Musculoskeletal
Studied dose
20 μg/day · subcutaneous · 3 monthsAs given in this study (human).
Source sentences
Summary
Median pain score dropped significantly in both groups with no group differences.
2 context sentences(design, population, supporting numbers)
Summary · context
Pelvic fracture patients were randomized to blinded daily subcutaneous teriparatide (TPTD) or placebo to assess healing and functional outcomes over 3 months.
Summary · context
This randomized, placebo-controlled study enrolled 35 patients (women and men >50 years old) within 4 weeks of pelvic fracture and evaluated the effect of blinded TPTD vs placebo over 3 months on fracture healing.
Report a problemFND-3438310003
04HumanRandomized controlled trialEfficacy outcome
In pelvic-fracture patients, CSPPS improved with teriparatide but not placebo, with significant group differences at two and three months.
In plain wordsIn pelvic-fracture patients, physical performance scores improved with teriparatide but not placebo, with group differences at two and three months.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseContinuous Summary Physical Performance Score
Study
n = 35
Comparator
Placebo
Outcome group
Exercise and physical function · Musculoskeletal
Studied dose
20 μg/day · subcutaneous · 3 monthsAs given in this study (human).
Source sentences
Summary
Both CSPPS and TUG improved in the teriparatide group, whereas there was no improvement in the placebo group (group difference p < 0.03 for CSPPS at 2 and 3 months).
2 context sentences(design, population, supporting numbers)
Summary · context
Pelvic fracture patients were randomized to blinded daily subcutaneous teriparatide (TPTD) or placebo to assess healing and functional outcomes over 3 months.
Summary · context
This randomized, placebo-controlled study enrolled 35 patients (women and men >50 years old) within 4 weeks of pelvic fracture and evaluated the effect of blinded TPTD vs placebo over 3 months on fracture healing.
Report a problemFND-3438310004
05HumanRandomized controlled trialEfficacy outcome
In pelvic-fracture patients, Timed Up and Go performance improved with teriparatide, whereas placebo showed no improvement.
In plain wordsIn pelvic-fracture patients, Timed Up and Go performance improved with teriparatide, while placebo showed no improvement.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseTimed Up and Go performance
Study
n = 35
Comparator
Placebo
Outcome group
Exercise and physical function · Musculoskeletal
Studied dose
20 μg/day · subcutaneous · 3 monthsAs given in this study (human).
Source sentences
Summary
Both CSPPS and TUG improved in the teriparatide group, whereas there was no improvement in the placebo group (group difference p < 0.03 for CSPPS at 2 and 3 months).
2 context sentences(design, population, supporting numbers)
Summary · context
Pelvic fracture patients were randomized to blinded daily subcutaneous teriparatide (TPTD) or placebo to assess healing and functional outcomes over 3 months.
Summary · context
This randomized, placebo-controlled study enrolled 35 patients (women and men >50 years old) within 4 weeks of pelvic fracture and evaluated the effect of blinded TPTD vs placebo over 3 months on fracture healing.
Report a problemFND-3438310005

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials2

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

2 trials · 1 not yet recruiting · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

Not yet recruitingPhase 1/2NCT06303284

PROactive HEALing in High-Risk Pelvic and Non-hip Lower Extremity Fragility Fractures (PRO HEAL Pilot)

University of Calgaryn = 54est. 15 Mar 2027 to est. 17 Mar 2031

Lower Extremity Fractures · Pelvis · Acetabulum

Trial page ClinicalTrials.govUpdated 6 Oct 2026

CompletedPhase 2Results postedNCT02972424

PTH(1-34) and Pelvic Fracture Healing - a Randomized Controlled Trial

Hospital for Special Surgery, New Yorkn = 351 May 2017 to 8 Jul 2021

Osteoporotic Fractures

Trial page ClinicalTrials.govUpdated 27 Jul 2022

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.